These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16806797)

  • 21. Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
    Barnes MN; Chhieng DF; Dreher M; Jones JL; Grizzle WE; Jones L; Talley L; Partridge EE
    Gynecol Oncol; 2005 Sep; 98(3):376-82. PubMed ID: 15993933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.
    Olivares C; Bilotas M; Buquet R; Borghi M; Sueldo C; Tesone M; Meresman G
    Hum Reprod; 2008 Dec; 23(12):2701-8. PubMed ID: 18716040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.
    Twardowski PW; Smith-Powell L; Carroll M; VanBalgooy J; Ruel C; Frankel P; Synold TW
    Cancer Invest; 2008 Feb; 26(1):53-9. PubMed ID: 18181046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer].
    Guo GL; Yang GL; Li ZY; You J; Yang K; Huang DP; Hu XQ; Zhang XH
    Zhonghua Wai Ke Za Zhi; 2008 Jan; 46(2):132-5. PubMed ID: 18509974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
    Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
    Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
    Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prophylactic effect of a selective COX-2 inhibitor celecoxib on carcinogen-induced gastric premalignant lesions in rats].
    Tang BD; Zeng ZR; Hu PJ
    Ai Zheng; 2006 Oct; 25(10):1205-9. PubMed ID: 17059761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
    J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
    Caine GJ; Stonelake PS; Lip GY; Blann AD
    Cancer Lett; 2007 Apr; 248(1):131-6. PubMed ID: 16891056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot randomized phase II study of celecoxib in oral premalignant lesions.
    Papadimitrakopoulou VA; William WN; Dannenberg AJ; Lippman SM; Lee JJ; Ondrey FG; Peterson DE; Feng L; Atwell A; El-Naggar AK; Nathan CO; Helman JI; Du B; Yueh B; Boyle JO
    Clin Cancer Res; 2008 Apr; 14(7):2095-101. PubMed ID: 18381950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
    Gonda T; Okada N; Nakada H; Yokoyama M; Miyazaki T; Ishibashi K; Ishida H; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1841-4. PubMed ID: 17212123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential.
    Yang P; Zhang Y; Ping L; Gao XM
    Int Immunopharmacol; 2007 Nov; 7(11):1414-21. PubMed ID: 17761345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.
    Kolev Y; Uetake H; Iida S; Ishikawa T; Kawano T; Sugihara K
    Ann Surg Oncol; 2007 Oct; 14(10):2738-47. PubMed ID: 17687613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
    Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
    Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
    Kahán Z; Spanik S; Wagnerova M; Skacel T; Planko B; Fitzthum E; Lindner E; Soldatenkova V; Zielinski CC; Brodowicz T
    Breast Cancer Res Treat; 2008 Dec; 112(3):557-63. PubMed ID: 18189160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
    Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemopreventive effect of celecoxib in gastric cancer.
    Futagami S; Suzuki K; Hiratsuka T; Shindo T; Hamamoto T; Ueki N; Kusunoki M; Miyake K; Gudis K; Tsukui T; Sakamoto C
    Inflammopharmacology; 2007 Feb; 15(1):1-4. PubMed ID: 17323186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Influence of neoadjuvant therapy on VEGFR-2 levels in tumor and blood serum from breast cancer patients].
    Kim EA; Gershteĭn ES; Vysotskaia IV; Letiagin VP; Kushlinsiĭ NE
    Vopr Onkol; 2008; 54(3):287-93. PubMed ID: 18652232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.